431 related articles for article (PubMed ID: 36057761)
1. Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations.
Smith MC; Klein P; Krauss GL; Rashid S; Seiden LG; Stern JM; Rosenfeld WE
Neurol Ther; 2022 Dec; 11(4):1705-1720. PubMed ID: 36057761
[TBL] [Abstract][Full Text] [Related]
2. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
Carreño M; Gil-Nagel A; Serratosa JM; Toledo M; Rodriguez-Uranga JJ; Villanueva V
Epilepsia Open; 2024 Jun; 9(3):1051-1058. PubMed ID: 38573131
[TBL] [Abstract][Full Text] [Related]
3. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.
Rosenfeld WE; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Krauss GL; Sperling MR; Vossler DG; Klein P; Wechsler R
Epilepsia; 2021 Dec; 62(12):3016-3028. PubMed ID: 34633074
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations.
Steinhoff BJ; Ben-Menachem E; Klein P; Peltola J; Schmitz B; Thomas RH; Villanueva V
Ther Adv Neurol Disord; 2024; 17():17562864241256733. PubMed ID: 38883228
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study.
Peña-Ceballos J; Moloney PB; Munteanu T; Doyle M; Colleran N; Liggan B; Breen A; Murphy S; El-Naggar H; Widdess-Walsh P; Delanty N
Epilepsia; 2023 May; 64(5):1225-1235. PubMed ID: 36790345
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Rosenfeld WE; Nisman A; Ferrari L
Epilepsy Res; 2021 May; 172():106592. PubMed ID: 33662894
[TBL] [Abstract][Full Text] [Related]
7. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
Sperling MR; Klein P; Aboumatar S; Gelfand M; Halford JJ; Krauss GL; Rosenfeld WE; Vossler DG; Wechsler R; Borchert L; Kamin M
Epilepsia; 2020 Jun; 61(6):1099-1108. PubMed ID: 32396252
[TBL] [Abstract][Full Text] [Related]
8. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study.
Serrano-Castro PJ; Ramírez-García T; Cabezudo-Garcia P; Garcia-Martin G; De La Parra J
CNS Drugs; 2024 Feb; 38(2):141-151. PubMed ID: 38265735
[TBL] [Abstract][Full Text] [Related]
9. Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: A retrospective review.
Becker DA; Demko SA
Epilepsy Res; 2023 Nov; 197():107242. PubMed ID: 37871541
[TBL] [Abstract][Full Text] [Related]
10. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study.
Aboumatar S; Ferrari L; Stern S; Wade CT; Weingarten M; Connor GS; Rosenfeld WE
Epilepsy Res; 2024 Feb; 200():107306. PubMed ID: 38340681
[TBL] [Abstract][Full Text] [Related]
11. Treatment simplification to optimize cenobamate effectiveness and tolerability: A real-world retrospective study in Spain.
Rodríguez-Uranga JJ; Sánchez-Caro JM; Hariramani Ramchandani R
Epilepsia Open; 2024 May; ():. PubMed ID: 38800945
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study.
O'Dwyer R; Stern S; Wade CT; Guggilam A; Rosenfeld WE
Drugs Aging; 2024 Mar; 41(3):251-260. PubMed ID: 38446341
[TBL] [Abstract][Full Text] [Related]
13. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva V; Serratosa JM; Toledo M; Ángel Calleja M; Navarro A; Sabaniego J; Pérez-Domper P; Álvarez-Barón E; Subías S; Gil A
Epilepsy Behav; 2023 Feb; 139():109054. PubMed ID: 36603345
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review.
Wheless JW
Expert Rev Neurother; 2020 Nov; 20(11):1085-1098. PubMed ID: 33031714
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability.
Roberti R; De Caro C; Iannone LF; Zaccara G; Lattanzi S; Russo E
CNS Drugs; 2021 Jun; 35(6):609-618. PubMed ID: 33993416
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications.
Brandt C; Sánchez-Álvarez JC; Steinhoff BJ; Milanov I; Serratosa JM
Seizure; 2022 Mar; 96():86-93. PubMed ID: 35168142
[TBL] [Abstract][Full Text] [Related]
17. Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy-expert opinion.
Steinhoff BJ; Rosenfeld WE; Serratosa JM; Brandt C; Klein P; Toledo M; Krauss GL
Epilepsy Behav; 2021 Oct; 123():108270. PubMed ID: 34509033
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
Sperling MR; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Klein P; Krauss GL; Vossler DG; Wechsler R; Ferrari L; Grall M; Rosenfeld WE
Epilepsia; 2021 Dec; 62(12):3005-3015. PubMed ID: 34633084
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials.
Moseley B; Bourikas D; Dimova S; Elmoufti S; Borghs S
Adv Ther; 2024 Apr; 41(4):1746-1758. PubMed ID: 38356105
[TBL] [Abstract][Full Text] [Related]
20. Onset of efficacy and adverse events during Cenobamate titration period.
Steinhoff BJ; Ben-Menachem E; Brandt C; García Morales I; Rosenfeld WE; Santamarina E; Serratosa JM
Acta Neurol Scand; 2022 Sep; 146(3):265-275. PubMed ID: 35711112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
